Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Assess Safety and Efficacy of PRL3-zumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT07547228 is registered in ClinicalTrials.gov with Intra-IMMUSG Pte Ltd as lead sponsor.

NCT NCT07547228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07547228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Assess Safety and Efficacy of PRL3-zumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Lead sponsor
Intra-IMMUSG Pte Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 11, 2025
Completion date
July 7, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age related macular degeneration